These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 761378)

  • 41. Interference of spironolactone metabolites in a digoxin radioimmunoassay.
    Crothers DC
    Ther Drug Monit; 1989; 11(1):113-4. PubMed ID: 2911846
    [No Abstract]   [Full Text] [Related]  

  • 42. Reduced variation of tracer binding in digoxin radioimmunoassay by use of (125I)-labeled tyrosine-methyl-ester derivative: relation of thyroxine concentration to binding.
    Kroening BH; Weintraub M
    Clin Chem; 1976 Oct; 22(10):1732-4. PubMed ID: 975522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin.
    Müller H; Bräuer H; Resch B
    Clin Chem; 1978 Apr; 24(4):706-9. PubMed ID: 639280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inter and intra laboratory variation of digoxin radioimmunoassay in Sweden.
    Bergdahl B; Dahlström G; Molin L; Bertler A
    Acta Pharmacol Toxicol (Copenh); 1979 Jul; 45(1):66-72. PubMed ID: 474161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measurement of cyclosporine concentrations in whole blood: HPLC and radioimmunoassay with a specific monoclonal antibody and 3H- or 125I-labeled ligand compared.
    Wolf BA; Daft MC; Koenig JW; Flye MW; Turk JW; Scott MG
    Clin Chem; 1989 Jan; 35(1):120-4. PubMed ID: 2642760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Serum dixogin determination. Clinical significance, results and error consideration based on comparative studies with different radioimmunoassays].
    Müller H; Graul EH; Müller L
    Z Kardiol; 1975 Dec; 64(2):1123-39. PubMed ID: 814731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly specific radioimmunoassay for digoxin using a monoclonal antibody selected for lack of interference by digoxin-like immunoreactive substances in cord blood sera.
    Wahyono D; Piechaczyk M; Scherrmann JM; Girard C; Grenier J; Mani JC; Bastide JM; Pau B
    Ther Drug Monit; 1991 Mar; 13(2):113-9. PubMed ID: 2053117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Radioimmunoassay of serum digoxin levels. Technical aspects (author's transl)].
    Galland F; Gallois Y; Jallet P
    Pathol Biol (Paris); 1981 Oct; 29(8):486-90. PubMed ID: 7029427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of cyclosporine determinations in whole blood by three different methods. HPLC, 125I RIA and 3H RIA.
    Huang WY; Lipsey AI; Cheng MH
    Am J Clin Pathol; 1987 Apr; 87(4):528-32. PubMed ID: 3826016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Problems with 125I-labeled tyrosyl ligands in digoxin RIA.
    Kroening BH; Weintraub M
    Clin Chem; 1980 Feb; 26(2):360-1. PubMed ID: 7353305
    [No Abstract]   [Full Text] [Related]  

  • 51. "Lack of clinically significant interference by spironolactone with the Axsym Digoxin II assay" only applies to low-dose therapy with spironolactone.
    Steimer W
    Ther Drug Monit; 2003 Aug; 25(4):484-5. PubMed ID: 12883235
    [No Abstract]   [Full Text] [Related]  

  • 52. [Cardiac glycosides and metabolites--problems of recovery in tissue extracts. Separation of visible substance spots in the nanogram range (author's transl)].
    Aderjan R; Doster S; Petri H; Schmidt G
    Z Rechtsmed; 1979 Aug; 83(3):201-7. PubMed ID: 494819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The question of cumulation of digoxin metabolites in renal failure.
    Gibson TP; Nelson HA
    Clin Pharmacol Ther; 1980 Feb; 27(2):219-23. PubMed ID: 7353343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Plasma-digoxin concentration in patients at time of hospital admission (author's transl)].
    Lichey J; Schröder R; Rietbrock N
    Dtsch Med Wochenschr; 1977 Jul; 102(29):1056-60. PubMed ID: 891379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of two digoxin radioimmunoassay procedures in which 125I-labeled digoxin is used.
    Kuczala ZJ; Ahluwalia GS
    Clin Chem; 1976 Feb; 22(2):193-7. PubMed ID: 1248120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of analysis of digoxin in cardiac patients by HPLC and RIA.
    Kwong E; Embree L; McErlane KM
    Res Commun Chem Pathol Pharmacol; 1990 Apr; 68(1):121-4. PubMed ID: 2345802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A rapid, simple assay for digoxin.
    Greenwood H; Howard M; Landon J
    J Clin Pathol; 1974 Jun; 27(6):490-4. PubMed ID: 4411728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of clinically significant interference by spironolactone with the AxSym Digoxin II assay.
    Howard G; Barclay M; Florkowski C; Moore G; Roche A
    Ther Drug Monit; 2003 Feb; 25(1):112-3. PubMed ID: 12548154
    [No Abstract]   [Full Text] [Related]  

  • 59. Interference of digoxin-like immunoreactive substances with three digoxin immunoassays in patients with various degrees of renal function.
    Pleasants RA; Gadsden RH; McCormack JP; Piveral K; Sawyer WT
    Clin Pharm; 1986 Oct; 5(10):810-6. PubMed ID: 3780148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precision of digoxin radioimmunoassays and matrix effects: four kits compared.
    Bergdähl B; Molin L
    Clin Biochem; 1981 Apr; 14(2):67-71. PubMed ID: 7296815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.